Amarin Fights Flames Of Investor Unrest
Confident Of European Growth For Vazkepa
Executive Summary
Derided by largest shareholder Sarissa as ‘dawdling’ and ‘lackadaisical,’ the board at Amarin has come out fighting, saying that a strategy of growing its heart drug in Europe will pay dividends.
You may also be interested in...
Finance Watch: FibroGen, Amarin And Others Downsize To Survive
Restructuring Edition: FibroGen follows its clinical setback with a 32% reduction in force, cutting 104 jobs. Also, Amarin named a new CEO, but cut all US sales and 30% of non-sales US roles, and 9 Meters is headed for dissolution after Chapter 7 bankruptcy, while several others seek strategic alternatives.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
C4XD Delisting Highlights Funding Frustration For UK Biotechs
The Manchester-based group has had enough of being undervalued in the public markets and is going private again.